Boaz Weinstein’s Cardio Diagnostics Holdings Inc Warrant CDIOW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3K Hold
199,839
﹤0.01% 389
2026
Q1
$3.16K Hold
199,839
﹤0.01% 373
2025
Q4
$4.78K Hold
199,839
﹤0.01% 324
2025
Q3
$4.09K Hold
199,839
﹤0.01% 306
2025
Q2
$3K Hold
199,839
﹤0.01% 304
2025
Q1
$7.01K Hold
199,839
﹤0.01% 235
2024
Q4
$16.6K Hold
199,839
﹤0.01% 230
2024
Q3
$7.77K Hold
199,839
﹤0.01% 294
2024
Q2
$7.18K Hold
199,839
﹤0.01% 328
2024
Q1
$21.3K Hold
199,839
﹤0.01% 304
2023
Q4
$34.8K Hold
199,839
﹤0.01% 344
2023
Q3
$8.2K Hold
199,839
﹤0.01% 508
2023
Q2
$37.7K Hold
199,839
﹤0.01% 437
2023
Q1
$63.9K Sell
199,839
-35,758
-15% -$8.39K ﹤0.01% 523
2022
Q4
$11.7K Hold
235,597
﹤0.01% 789
2022
Q3
$39K Hold
235,597
﹤0.01% 875
2022
Q2
$31K Hold
235,597
﹤0.01% 955
2022
Q1
$46K Buy
+235,597
New +$56K ﹤0.01% 875

Other funds holding CDIOW

Boaz Weinstein's CDIOW Position: Q2 2026 in Review

Boaz Weinstein held its Cardio Diagnostics Holdings Inc Warrant (CDIOW) position steady in Q2 2026 at 199,839 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #389.

Boaz Weinstein first reported a position in CDIOW in Q1 2022 and has held it in 18 quarters since. The position peaked at $63.9K in Q1 2023. 7 funds tracked by Wall St. Rank hold CDIOW as of Q2 2026.

  • Boaz Weinstein held 199,839 shares of Cardio Diagnostics Holdings Inc Warrant worth $3K as of Q2 2026.
  • Boaz Weinstein left its Cardio Diagnostics Holdings Inc Warrant share count unchanged in Q2 2026.
  • Cardio Diagnostics Holdings Inc Warrant made up ﹤0.01% of Boaz Weinstein's portfolio in Q2 2026, its #389 holding.
  • Boaz Weinstein first reported a position in Cardio Diagnostics Holdings Inc Warrant in Q1 2022 and has held it in 18 quarters since.
  • Boaz Weinstein's Cardio Diagnostics Holdings Inc Warrant position peaked at $63.9K in Q1 2023.
  • 7 funds tracked by Wall St. Rank held Cardio Diagnostics Holdings Inc Warrant as of Q2 2026.

Based on Saba Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.